ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 950,17
0,00%
Dow Jones
44 544,66
-0,75%
DAX
21 711,43
0,00%
Brent Oil
76,55
0,26%
Bitcoin
95 220,99
-2,54%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Menlo Therapeutics Inc (MNLO) Cours

Menlo Therapeutics Inc

Menlo Therapeutics Inc (MNLO)

NASDAQ
1,35
0,00
(0,00%)
Fermé 03 Février 10:00PM
Retardé de 15 minutes
0,00
0,00
(0,00%)
Après les heures de négociation: -
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
1,35
Prix Achat
1,36
Prix Vente
1,37
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Cap du marché
18,842M
Clôture Veille
1,35
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
-
Actions en circulation
13 957 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-1,15
Bénéfice par action (BPA)
-2,04
Chiffre d'affairess
424k
Bénéfice net
-28,45M

À propos de Menlo Therapeutics Inc

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
vynetherapeutics.com
Siège social
Wilmington, Delaware, USA
Fondé
-

MNLO Dernières nouvelles

Plus de nouvelles

Robbins Geller Rudman & Dowd LLP Announce Proposed Settlement in the Menlo Therapeutics Inc. Securities Settlement

The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Menlo Therapeutics Inc. Securities Settlement: SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF...

22 Mai 2020
Business Wire

Menlo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

REDWOOD CITY, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the...

03 Mars 2020
GlobeNewswire Inc.

Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced results from its Phase 2 clinical trial...

26 Février 2020
GlobeNewswire Inc.

Menlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chr...

REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast...

26 Février 2020
GlobeNewswire Inc.

Menlo Therapeutics Announces Publication of Phase 2 Results for Serlopitant for the Treatment of Pruritus Associated with Pso...

REDWOOD CITY, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment...

05 Février 2020
GlobeNewswire Inc.

Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment...

27 Novembre 2019
GlobeNewswire Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd. PR Newswire NEW YORK, Nov. 12, 2019 NEW YORK, Nov. 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible...

12 Novembre 2019
PR Newswire (US)

Menlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program Updates

REDWOOD CITY, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment...

31 Octobre 2019
GlobeNewswire Inc.

Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis

- Pivotal results expected in March/April 2020 - - Details of the program to be reviewed at company’s Investor Day today in NY - REDWOOD CITY, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Menlo...

29 Octobre 2019
GlobeNewswire Inc.

Menlo Therapeutics to Host Investor Day October 29, 2019

-Management to Review Late Stage Development, NDA-readiness and Commercial Opportunity of Serlopitant- -Discussion to Feature two Prominent Key Opinion Leaders Well Versed in the Unmet Needs of...

22 Octobre 2019
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

MNLO - Frequently Asked Questions (FAQ)

What is the current Menlo Therapeutics share price?
The current share price of Menlo Therapeutics is US$ 1,35
How many Menlo Therapeutics shares are in issue?
Menlo Therapeutics has 13 957 000 shares in issue
What is the market cap of Menlo Therapeutics?
The market capitalisation of Menlo Therapeutics is USD 18,84M
What is the 1 year trading range for Menlo Therapeutics share price?
Menlo Therapeutics has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of Menlo Therapeutics?
The price to earnings ratio of Menlo Therapeutics is -1,15
What is the cash to sales ratio of Menlo Therapeutics?
The cash to sales ratio of Menlo Therapeutics is 77,3
What is the reporting currency for Menlo Therapeutics?
Menlo Therapeutics reports financial results in USD
What is the latest annual turnover for Menlo Therapeutics?
The latest annual turnover of Menlo Therapeutics is USD 424k
What is the latest annual profit for Menlo Therapeutics?
The latest annual profit of Menlo Therapeutics is USD -28,45M
What is the registered address of Menlo Therapeutics?
The registered address for Menlo Therapeutics is 1521 CONCORD PIKE SUITE 201, WILMINGTON, DELAWARE, 19810
What is the Menlo Therapeutics website address?
The website address for Menlo Therapeutics is vynetherapeutics.com
Which industry sector does Menlo Therapeutics operate in?
Menlo Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
TCTMTCTM Kids IT Education Inc
US$ 0,764
(321,87%)
731,1M
REBNReborn Coffee Inc
US$ 3,31
(63,05%)
55,54M
FCUVFocus Universal Inc
US$ 5,87
(56,62%)
1,73M
SOPASociety Pass Inc
US$ 1,54
(56,50%)
13,87M
CYCNCyclerion Therapeutics Inc
US$ 3,92
(54,33%)
82,57M
ENVBEnveric Biosciences Inc
US$ 2,0899
(-46,41%)
1,58M
NIVFNewGenIvf Group Ltd
US$ 0,1489
(-42,51%)
14,91M
GLSTGlobal Star Acquisition Inc
US$ 8,83
(-39,10%)
23,93k
PRPHProPhase Labs Inc
US$ 0,2633
(-38,02%)
900,48k
SPGCSacks Parente Golf Inc
US$ 0,5601
(-37,86%)
7,42M
TCTMTCTM Kids IT Education Inc
US$ 0,764
(321,87%)
729,72M
NVDANVIDIA Corporation
US$ 120,07
(-3,67%)
388,54M
RIMEAlgorhythm Holdings Inc
US$ 0,02565
(5,12%)
338,75M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0355
(-11,25%)
236,29M
CLEUChina Liberal Education Holdings Ltd
US$ 0,1938
(30,77%)
234,8M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
MNLO
Menlo Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces